These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 32407458

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Identification of symbol digit modality test score extremes in Huntington's disease.
    Braisch U, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M, REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.
    Am J Med Genet B Neuropsychiatr Genet; 2019 Apr; 180(3):232-245. PubMed ID: 30788902
    [Abstract] [Full Text] [Related]

  • 3. Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.
    Kloos AD, Kegelmeyer DA, Fritz NE, Daley AM, Young GS, Kostyk SK.
    J Huntingtons Dis; 2017 Apr; 6(4):363-370. PubMed ID: 29254103
    [Abstract] [Full Text] [Related]

  • 4. Reaction time and rhythm of movement in Huntington's disease.
    Martínez Pueyo A, García-Ruiz PJ, Feliz CE, Garcia Caldentey J, Del Val J, Herranz A.
    J Neurol Sci; 2016 Mar 15; 362():115-7. PubMed ID: 26944129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bradykinesia in early Huntington's disease.
    Sánchez-Pernaute R, Künig G, del Barrio Alba A, de Yébenes JG, Vontobel P, Leenders KL.
    Neurology; 2000 Jan 11; 54(1):119-25. PubMed ID: 10636136
    [Abstract] [Full Text] [Related]

  • 7. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
    Lowe AJ, Sjödin S, Rodrigues FB, Byrne LM, Blennow K, Tortelli R, Zetterberg H, Wild EJ.
    PLoS One; 2020 Jan 11; 15(8):e0233820. PubMed ID: 32804976
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY, Achterberg WP, Gardiner SL, Roos RAC.
    Eur J Neurol; 2019 May 11; 26(5):780-785. PubMed ID: 30576046
    [Abstract] [Full Text] [Related]

  • 9. The Effect of Education on Symptom Onset and Severity of Huntington's Disease.
    Cain KK, Flanigan JL, Dalrymple WA, Patrie J, Harrison MB, Barrett MJ.
    Mov Disord Clin Pract; 2021 May 11; 8(4):555-562. PubMed ID: 33981788
    [Abstract] [Full Text] [Related]

  • 10. Rate of functional decline in Huntington's disease. Huntington Study Group.
    Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I.
    Neurology; 2000 Jan 25; 54(2):452-8. PubMed ID: 10668713
    [Abstract] [Full Text] [Related]

  • 11. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.
    Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R.
    J Neurol; 2004 Aug 25; 251(8):935-42. PubMed ID: 15316797
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing cognitive function in patients with Huntington's disease from China: A cross-sectional clinical study.
    Cheng YF, Liu KC, Yang TM, Xiao Y, Jiang QR, Huang JX, Zhang S, Wei QQ, Ou RW, Li CY, Gu XJ, Burgunder JM, Shang HF.
    Brain Behav; 2023 Nov 25; 13(11):e3258. PubMed ID: 37849450
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM, van der Grond J, Hafkemeijer A, Rombouts SA, Roos RA.
    Neuroimage Clin; 2016 Nov 25; 12():806-814. PubMed ID: 27830113
    [Abstract] [Full Text] [Related]

  • 15. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers.
    Li F, Li K, Li C, Luo S, PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group.
    J Huntingtons Dis; 2019 Nov 25; 8(3):323-332. PubMed ID: 31256145
    [Abstract] [Full Text] [Related]

  • 16. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP, Dumas EM, Schoonderbeek A, Wolthuis SC, van Zwet EW, Roos RA.
    Mov Disord; 2014 Mar 25; 29(3):320-6. PubMed ID: 24500841
    [Abstract] [Full Text] [Related]

  • 17. Assessing Decline: Visualising Progression in Huntington's Disease using a Clinical Dashboard with Enroll-HD Data.
    Walker T, Ghosh B, Kipps C.
    J Huntingtons Dis; 2017 Mar 25; 6(2):139-147. PubMed ID: 28550266
    [Abstract] [Full Text] [Related]

  • 18. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R, Stout JC, Labuschagne I, Say M, Justo D, Coleman A, Dumas EM, Hart E, Owen G, Durr A, Leavitt BR, Roos R, O'Regan A, Langbehn D, Tabrizi SJ, Frost C.
    J Huntingtons Dis; 2014 Mar 25; 3(2):197-207. PubMed ID: 25062862
    [Abstract] [Full Text] [Related]

  • 19. Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.
    Beglinger LJ, Duff K, Allison J, Theriault D, O'Rourke JJ, Leserman A, Paulsen JS.
    J Clin Exp Neuropsychol; 2010 Jul 25; 32(6):573-8. PubMed ID: 19882420
    [Abstract] [Full Text] [Related]

  • 20. Ideomotor limb apraxia in Huntington's disease: a case-control study.
    Hödl AK, Hödl E, Otti DV, Herranhof B, Ille R, Bonelli RM.
    J Neurol; 2008 Mar 25; 255(3):331-9. PubMed ID: 18305889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.